Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026)
Gilead Sciences (GILD) posted Amortizatization of Intangibles of $596.0 million for Q1 2026, little changed quarter-over-quarter from $597.0 million in Q4 2025, and down 0.5% year-on-year from $599.0 million in Q1 2025.
Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Amortizatization of Intangibles for 18 consecutive years, with $596.0 million the latest figure, recorded in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $596.0 million, down 0.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (changed 0.08% YoY), and the FY2025 annual result was $2.4 billion, changed 0.17% from the prior year.
- Amortizatization of Intangibles was $596.0 million for Q1 2026 at Gilead Sciences, roughly flat from $597.0 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $599.0 million in Q1 2025 and troughed at $445.0 million in Q1 2022.
- Average Amortizatization of Intangibles over 5 years is $558.3 million, with a median of $596.0 million recorded in 2024.
- Year-over-year, Amortizatization of Intangibles surged 34.38% in 2023 and fell 0.5% in 2026.
- Over 5 years, Amortizatization of Intangibles stood at $445.0 million in 2022, then jumped by 34.16% to $597.0 million in 2023, then advanced by 0.17% to $598.0 million in 2024, then retreated by 0.17% to $597.0 million in 2025, then fell by 0.17% to $596.0 million in 2026.
- Per Business Quant data, the three most recent Amortizatization of Intangibles figures were $596.0 million in Q1 2026, $597.0 million in Q4 2025, and $596.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amort. of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 1.70 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 107.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 596.00 Mn |
| Mar 31, 2026 | 596.00 Mn |
| Dec 31, 2025 | 597.00 Mn |
| Dec 31, 2025 | 597.00 Mn |
| Sep 30, 2025 | 596.00 Mn |
| Sep 30, 2025 | 596.00 Mn |
| Jun 30, 2025 | 598.00 Mn |
| Jun 30, 2025 | 598.00 Mn |
| Mar 31, 2025 | 599.00 Mn |
| Mar 31, 2025 | 599.00 Mn |
| Dec 31, 2024 | 598.00 Mn |
| Dec 31, 2024 | 598.00 Mn |
| Sep 30, 2024 | 596.00 Mn |
| Sep 30, 2024 | 596.00 Mn |
| Jun 30, 2024 | 596.00 Mn |
| Jun 30, 2024 | 596.00 Mn |
| Mar 31, 2024 | 596.00 Mn |
| Mar 31, 2024 | 596.00 Mn |
| Dec 31, 2023 | 597.00 Mn |
| Dec 31, 2023 | 597.00 Mn |